Optimized human cell products for research
and drug discovery

Neonatal Diabetes Pancreatic Cells

DefiniGEN Neonatal Diabetes Disease Modelled Pancreatic Cells

DefiniGEN’s neonatal diabetes human pancreatic cells display a mutation in the KCNJ11 gene encoding Kir6.2 subunit of potassium channels – CAT>CGT at codon 201 and are an effective model of this form of monogenic diabetes. Neonatal diabetes mellitus (NDM) is a rare but potentially devastating metabolic disorder characterized by hyperglycemia combined with low levels of insulin. The neonatal diabetes cell products display the disease phenotype in combination with general function comparable to human primary pancreatic islets. Phenotypic analysis of the cells using GSIS assays demonstrates that the insulin response to glucose challenge is dysfunctional in these disease modelled cell products in contrast to DefiniGEN’s isogenic wild-type control pancreatic cell products. These cell products can offer disease modelling and drug discovery researchers unprecedented tool for elucidating the underlying mechanisms of this key form of monogenic diabetes.

Product Specification

Product ID:
Cell Number:
10 million viable cells
Neonatal Diabetes
Disease Modelling and Drug Discovery

Pancreatic Cell Morphology

             Def- PANC WT                            Def-PANC Neonatal

Pancreatic WT Cell MorphologyPancreatic Neonatal Cell Morphology

Figure 1. Morphology of pancreatic cells grown as a monolayer.

Disease Circuit Verification

Neonatal diabetes disease model with confirmed mutation in KCNJ11 gene encoding Kir6.2 subunit of potassium channels – CAT>CGT at codon 201 – isogenic control available

Disease Circuit Verification

Figure 2. Sanger sequencing showing heterozygous KCNJ11 mutation with single base change (CAT>CGT) at codon 201 in the gene encoding for the ATP-sensitive potassium channel subunit Kir6.2.

Glucose Stimulated Insulin Secretion Assay

Glucose Cycling GSIS Response

Figure 3. Def-PANC WT isogenic control shows expected glucose cycling GSIS response at low and high glucose concentrations. The Def-PANC Neonatal disease model shows dysfunction in its glucose responsive insulin production in contrast to the isogenic WT control. Genetic information and phenotypic GSIS response confirms that Def-PANC Neonatal cells are an effective model of neonatal diabetes.

We recommend that you use our online system to identify the products of interest and their respective product codes. To order we will require the following information:

Product code(s) of the item(s) you wish to order (e.g. Def-PANC NEONATAL)
Your name, email address, title and organization
Shipping address and billing address with contact names
Purchase Order number if you have one
Telephone number

For further information please contact us: